| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Sep'18 | Jun'18 |
|---|---|---|---|---|---|---|
Collaboration revenue | ||||||
19,085 | 20,789 | 21,244 | 20,312 | 0 | 0 | 0 |
Operating expenses: | ||||||
Research and development, net | ||||||
34,233 | 33,640 | 25,615 | 22,787 | 0 | 0 | 0 |
General and administrative | ||||||
13,319 | 12,662 | 14,681 | 19,033 | 0 | 0 | 0 |
Total operating expenses | ||||||
47,552 | 46,302 | 40,296 | 41,820 | 0 | 0 | 0 |
Loss from operations | ||||||
-28,467 | -25,513 | -19,052 | -21,508 | 0 | 0 | 0 |
Loss from equity-method investment | ||||||
93 | -32 | -32 | -382 | 0 | 0 | 0 |
Finance expense, net | ||||||
-510 | -446 | -171 | 118 | 0 | 0 | 0 |
Net loss | ||||||
-28,884 | -25,991 | -19,255 | -21,772 | 0 | 0 | 0 |
Net loss per share, basic and diluted | ||||||
-0.67 | -0.84 | -0.56 | -0.07 | -0.68 | -0.42 | -0.99 |
Weighted-average shares outstanding, basic and diluted | ||||||
14,521 | 14,568 | 13,201 | 10,412 | 10,095 | 10,093 | 10,057 |
Comprehensive loss: | ||||||
Net loss | ||||||
-28,884 | -25,991 | -19,255 | -21,772 | 0 | 0 | 0 |
Unrealized gain on short-term investments | ||||||
- | - | - | - | - | 0 | 0 |
Comprehensive loss | ||||||
-28,884 | -25,991 | -19,253 | -21,763 | 0 | 0 | 0 |